PTCT
PTC Therapeutics Inc
62.70$
+0.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 42.9% | 64.3% | 65.3% | 70.9% | 69.6% | 80.1% | 87.2% | 86.3% | 75.9% | 78.4% | 78.6% | 80.5% | |
| 13.1% | 31.3% | 30.6% | 34.2% | 28.6% | 45.7% | 55.7% | 38.6% | 25.4% | 34.0% | 29.1% | 32.3% | |
| 23.4% | 46.2% | 49.4% | 57.1% | 55.0% | 66.8% | 76.3% | 75.5% | 63.8% | 67.1% | 66.0% | 68.6% | |
| 13.2% | 8.5% | 11.0% | 9.8% | 10.9% | 9.3% | 7.9% | 7.4% | 7.7% | 6.3% | 7.7% | 7.4% | |
| 2.8% | 1.6% | 1.7% | 1.7% | 1.9% | 1.4% | 0.8% | 1.3% | 2.0% | 2.7% | 2.6% | 2.8% | |
| 6.5% | 4.3% | 4.6% | 4.3% | 4.5% | 4.8% | 3.1% | 3.1% | 3.1% | 2.8% | 2.9% | 2.5% | |
| 33.6% | 20.0% | 18.4% | 17.2% | 17.9% | 7.0% | 4.5% | 5.5% | 15.0% | 13.4% | 13.3% | 12.4% | |
| 153.2% | 143.2% | 149.9% | 151.1% | 157.2% | 164.4% | 107.0% | 107.8% | 105.9% | 107.1% | 106.3% | 105.1% | |
| 39.1% | 31.8% | 32.1% | 31.8% | 33.2% | 34.1% | 22.4% | 23.8% | 32.8% | 33.4% | 32.2% | 23.7% | |
| 1.1% | 11.1% | 0.9% | 0.8% | 0.9% | 15.9% | 0.6% | 0.6% | 11.4% | 20.2% | 10.6% | 2.3% | |
| 1.5% | 0.3% | 1.5% | 1.3% | 0.7% | 1.0% | 0.6% | 1.0% | 1.4% | 1.6% | 0.9% | 1.2% | |
| 45.5% | 100.4% | 15.9% | 14.9% | 15.5% | 123.7% | 10.8% | 10.9% | – | 69.9% | – | 16.5% | |
| -53.2% | -43.2% | -49.9% | -51.1% | -57.2% | -64.4% | -7.0% | -7.8% | -5.9% | -7.1% | -6.3% | -5.1% | |
| -248.3% | -173.2% | -188.6% | -181.3% | -194.4% | -213.9% | -104.7% | -108.0% | -107.0% | -102.3% | -103.4% | -88.7% | |
| 6.0% | 4.0% | 4.3% | 4.0% | 4.2% | 4.5% | 3.3% | 3.0% | 3.3% | 2.8% | 2.9% | 2.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.